Joshua Silverman - Jan 20, 2023 Form 4 Insider Report for Petros Pharmaceuticals, Inc. (PTPI)

Role
Director
Signature
/s/ Mitchell Arnold, attorney-in-fact
Stock symbol
PTPI
Transactions as of
Jan 20, 2023
Transactions value $
$0
Form type
4
Date filed
1/25/2023, 03:17 PM
Previous filing
Dec 20, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTPI Common Stock Options Exercise +2.52K +125.75% 4.52K Jan 20, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTPI Restricted Stock Units Options Exercise $0 -2.52K -100% $0.00* 0 Jan 20, 2023 Common Stock 2.52K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.
F2 On December 22, 2021, the reporting person was granted 2,515 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.
F3 Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.